anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide a method for repairing a fiber-reinforced composite structure using a carbon nanotube, a fiber and a thermosetting resin while maintaining original electromagnetic and lightning strike protection.  <P>SOLUTION: The method according to an embodiment of the present invention comprises preparing a damaged area to be repaired, preparing a repair patch made of a nanotube for the damaged area, adhering the repair patch to the damaged area and curing the repair patch, wherein the repair patch is that for a composite structure having a conductive layer. According to the embodiment, the repair patch includes a binder and a nanotube and is a repair resin for repairing a composite structure having a conductive layer. According to the embodiment, the repair layer includes a resin and a nanotube and is a putty for repairing a composite structure having a conductive layer. According to the embodiment, the putty includes a base and a conductive carbon nanotube.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Combination antiviral therapy may be helpful in the treatment of SARS-CoV-2 infection; however, no clinical trial data are available, and combined use of direct-acting antivirals (DAA) and monoclonal antibodies (mAb) has been reported only anecdotally. To assess the cooperative effects of dual drug combinations in vitro, we used a VERO E6 cell-based in vitro system with the ancestral B.1 or the highly divergent BQ.1.1 virus to test pairwise combinations of the licensed DAA, including nirmatrelvir (NRM), remdesivir (RDV) and the active metabolite of molnupiravir (EIDD-1931) as well the combination of RDV with four licensed mAbs (sotrovimab, bebtelovimab, cilgavimab, tixagevimab; tested only with the susceptible B.1 virus). According to SynergyFinder 3.0 summary and weighted scores, all the combinations had an additive effect. Within DAA/DAA combinations, paired scores with the B.1 and BQ.1.1 variants were comparable. In the post hoc analysis weighting synergy by concentrations, several cases of highly synergistic scores were detected at specific drug concentrations, both for DAA/DAA and for RDV/mAb combinations. This was supported by in vitro confirmation experiments showing a more than a linear shift of a drug-effective concentration (IC50) at increasing concentrations of the companion drug, although the effect was prominent with DAA/DAA combinations and minimal or null with RDV/mAb combinations. These results support the cooperative effects of dual drug combinations in vitro, which should be further investigated in animal models before introduction into the clinic.
PROBLEM TO BE SOLVED: To obtain the subject compound in high yield by acylating a chlorine compound obtained by the chlorination of a diphenyl compound, oxidizing the acylated compound and hydrolyzing the product. SOLUTION: The objective compound of the formula V is produced by a process consisting of the 1st step comprising the chlorination of a compound of the formula I (X is O, etc.), with a chlorination agent (e.g. gaseous chlorine) preferably in the presence of a catalyst (e.g. propyl sulfide) to obtain a compound of the formula II ((m) is 1-3;  (n) is 1 or 2), the 2nd step comprising the acylation of the compound of the formula II with an acylation agent (e.g. acetyl chloride) preferably in the presence of a Lewis acid (e.g. aluminum chloride) by Friedel-Crafts reaction and the optional chlorination after acylation to obtain a compound of the formula III (R is a 1-8C alkyl, etc.), the 3rd step comprising the oxidization of the compound of the formula III by Baeyer-Villiger reaction to obtain a compound of the formula IV and the 4th step comprising the hydrolysis of the obtained compound of the formula IV.
To investigate the correlation between quantitative plaque parameters, the perivascular fat attenuation index, and myocardial ischaemia caused by haemodynamic impairment. Patients with stable angina who had invasive flow reserve fraction (FFR) assessment and coronary artery computed tomography (CT) angiography were retrospectively enrolled. A total of 138 patients were included in this study, which were categorized into the FFR < 0.75 group (n = 43), 0.75 ≤ FFR ≤ 0.8 group (n = 37), and FFR > 0.8 group (n = 58), depending on the range of FFR values. The perivascular FAI and CTA-derived parameters, including plaque length (PL), total plaque volume (TPV), minimum lumen area (MLA), and narrowest degree (ND), were recorded for the lesions. An FFR < 0.75 was defined as myocardial-specific ischaemia. The relationships between myocardial ischaemia and parameters such as the PL, TPV, MLA, ND, and FAI were analysed using a logistic regression model and receiver operating characteristic (ROC) curves to compare the diagnostic accuracy of various indicators for myocardial ischaemia. The PL, TPV, ND, and FAI were greater in the FFR < 0.75 group than in the grey area group and the FFR > 0.80 group (all p < 0.05). The MLA in the FFR < 0.75 group was lower than that in the grey area group and the FFR > 0.80 group (both P < 0.05). There were no significant differences in the PL, TPV, or ND between the grey area and the FFR > 0.80 group, but there was a significant difference in the FAI. The coronary artery lesions with FFRs ≤ 0.75 had the greatest FAI values. Multivariate analysis revealed that the perivascular FAI and PL density are significant predictors of myocardial ischaemia. The FAI has some predictive value for myocardial ischaemia (AUC = 0.781). After building a combination model using the FAI and plaque length, the predictive power increased (AUC, 0.781 vs. 0.918), and the change was statistically significant (P < 0.001). The combined model of PL + FAI demonstrated great diagnostic efficacy in identifying myocardial ischaemia caused by haemodynamic impairment; the lower the FFR was, the greater the FAI. Thus, the PL + FAI could be a combined measure to securely rule out myocardial ischaemia.
PURPOSE:To obtain a composition of an oxidation-sensitive compound, which is stable, can be easily handled and is desirable for use as foodstuffs, foods, and drugs by mixing an oxidation-sensitive compound with a coating material, a triglyceride and a complexing agent. CONSTITUTION:The subject composition comprises an oxidation-sensitive compound, a coating material, a triglyceride and a complexing agent. Said triglycerides include natural triglycerides, triglycerides regenerated from natural ones and synthetic triglycerides, and are desirably vegetable oils such as olive oil, soybean oil and peanut oil. Examples of said complexing agents include phytic acid, phosphoric acid, meta-, pyro- and poly-phosphoric acid and salts thereof. Examples of said coating materials include proteins, polysaccharides, sugar, antioxidants, flow aids and fillers. Examples of the oxidation-sensitive compounds include fat-soluble vitamins, carotenoids, retinoic acid, flavors and fragrances.
All study participants will receive the same study treatment. Study treatment will be dry powder mannitol 400 mg twice a day by oral inhalation (the contents of 10 capsules administered individually) for 14 days +/- 2 days.
In Brazil, cancer represents the leading cause of death by disease in children and adolescents from 1 to 19 years old. Neuroblastomas correspond to nearly 10% of all cancer diagnoses among children younger than 15 years of age, with an incidence of 1 case per 100,000 children of this age group. About 500 new cases of neuroblastoma (NB) are diagnosed annually in Brazil. The complexity and intensity of treatment result in several treatment-related toxicities (TRT) that make it challenging to maintain nutritional status in these nutritionally at-risk patients. In Brazil, up to 26% of undernutrition at diagnosis has been found in patients with solid tumors. In neuroblastoma, high prevalence rates of malnutrition have been reported elsewhere with up to 80% of children at diagnosis and 20-50% during treatment classified as undernourished. It's important to underscore that nutritional status is a modifiable risk factor, therefore it needs more attention and close monitoring. It is important to better comprehend the effect of treatment for neuroblastoma on nutritional status and body composition, for which prospective longitudinal studies are required. Therefore, in this prospective cohort study, the investigators will evaluate the fluctuations in nutritional status over the course of treatment in children with neuroblastoma at the study center in São Paulo, Brazil. The results of this study will drive the development of evidence-based guidelines for the nutritional care of children with neuroblastoma and set research priorities for subsequent investigations.
Surgical technique will be standardized and will be performed by the study team. The bougie size for the LSG will be 40Fr, and a standard 5-port LSG will be performed. Standard protocolized postoperative recovery for all bariatric patients will be employed, including liquid diet with vitamins for the first 2 weeks postoperatively, followed by introduction of solid foods after. A hiatal dissection will also be performed during initial surgery, followed by a cruroplasty with Ethibon 0 sutures, in an interrupted manner.
PURPOSE: To obtain a bacteriostatic agent suitable for suppressing poisonous bacteria in foods, cosmetics, etc., by compounding a specific glucopyrid as active component. CONSTITUTION: This bacteriostatic agent contains glucopyrid consisting of one kind or more of 2,3,4-tri-o-acylglucose of the formula as active component. A compound of the formula is a glucopyrid derived from upper cuticule of Lycopersicon pennellii Corr. a wild species of tomato which mainly distributes on extremely dried west slopes at low altitude in the Andes in Peru and secretes viscous secretion on the surface of its leaves, stokes, etc. The component is obtained by bringing parts of leaves, stokes, etc., to contact with an organic solvent such as chloroform or hexane and extracting them. Losing no activity by the influences of glucoses such as starch, the agent bacteriostatic is suitable for suppressing flat sour germs in hermetic container-packed foods or drinks which is kept at a warm temperature.
PURPOSE:A treatment of the skin for preventing, remedying, and treating effectively acne, preventing effectively dandruff when it is applied to the scalp, comprising a reaction product of an unsaturated aliphatic alcohol and sulfur as an active ingredient. CONSTITUTION:100pts.wt. aliphatic alcohol (preferably 6-36C straight-chain or branched chain alcohol) containing one or more unsaturated bonds in the molecule is reacted with 0.1-150pts.wt., preferably 0.5-50pts.wt. sulfur at 130-220 deg.C. 100pts.wt. total amount of treatment components is blended with 0.01-20pts.wt., preferably 0.1-10pts.wt. of the prepared reaction product. The reaction product has higher viscosity with rise in amount of sulfur, and the reaction product which is liquid at room temperature, viscous state, waxy state, or solid state is obtainable.
In a previous study, we used metabolomic techniques to identify a new metabolite of Danshen Dripping Pills called isopropyl 3-(3,4-dihydroxyphenyl)-2-hydroxypropanoate (IDHP), which has potential as a drug candidate for cardiovascular diseases. This study aimed to explore the protective effects of IDHP against septic myocardial injury, as well as its molecular mechanism. Wild type or GAS6 knockout mice injured by cecal ligation and puncture (CLP) were used to observe the effect of IDHP. Here, we found that a specific concentration of IDHP (60 mg/kg) significantly increased the survival rate of septic mice to about 75 % at 72 h post CLP, and showed improvements in sepsis score, blood biochemistry parameters, cardiac function, and myocardial tissue damage. Furthermore, IDHP inhibited myocardial oxidative stress, inflammatory response, apoptosis, and mitochondrial dysfunction. Molecularly, we discovered that IDHP treatment reversed the CLP-induced downregulation of GAS6, Axl, and p-AMPK/AMPK expression. In addition, GAS6 knockout reversed the positive effect of IDHP in septic mice, indicated by more severe myocardial tissue damage, oxidative stress, inflammatory response, and mitochondrial dysfunction. GAS6 knockout also resulted in decreased levels of GAS6, Axl, and p-AMPK/AMPK. Taken together, our study provides evidence that IDHP has significant cardioprotective effects against sepsis by regulating the GAS6/Axl-AMPK signaling pathway. This finding has important therapeutic potential for treating sepsis.
The invention discloses compound nano-silver emulsifiable paste and a preparation method thereof. The compound nano-silver emulsifiable paste is O/W or W/O type emulsifiable paste prepared from nano-silver and zinc oxide as main drugs by certain processes. Nano-silver has strong antibacterial effects and a wide antimicrobial spectrum and causes drug resistance of bacteria difficultly. Zinc oxide has convergence and wound heal promotion effects. The compound nano-silver emulsifiable paste prepared from nano-silver and zinc oxide has anti-infection and wound heal promotion effects. The compound nano-silver emulsifiable paste has treatment advantages of moisture exposed burn ointment and sulfadiazine silver cream and avoids treatment defects and adverse reactions of moisture exposed burn ointment and sulfadiazine silver cream. The compound nano-silver emulsifiable paste can be used for anti-infection treatment on burns and scalds, infected wounds caused by physical mechanical damages, and chronic surface ulcers, and promotion of wound heal. The compound nano-silver emulsifiable paste can also be used for treatment on skin diseases such as sores, carbuncles, furuncles, erysipelas and tinea caused by bacteria, fungi and viruses.
The goal will be to achieve the optimal functional result, defined as an FFR post PCI ≥ 0.95. Further stented segment post-dilatation will be mandatory if FFR post PCI \< 0.95. In case of a clear evidence of significant atheroma proximal or distal to the stented segment, the operators will be encouraged to optimize the functional result further by implanting additional stents.
This study investigates the correlation between circulating tumor cells (CTCs) in peripheral blood and the clinical characteristics and prognosis of advanced pediatric neuroblastoma (NB). We conducted a retrospective analysis of 144 children with advanced NB who underwent comprehensive treatment. Detailed clinical data were collected, and CTCs were detected using a negative enrichment method combined with immunofluorescence technology. Prognostic evaluation criteria and cutoff values for CTCs were established using ROC curve analysis. Univariate and Cox multivariate regression analyses identified independent risk factors impacting prognosis. Patients were categorized into high and low-expression groups based on optimal cutoff values determined with X-tile software. The high expression group had a significantly higher incidence of disease progression (p < 0.001), maximum tumor diameter ≥10 cm (p = 0.004), undifferentiated subtype (p = 0.034), and stage IV disease (p = 0.007) compared to the low expression group. CTCs were notably higher in patients with progression compared to those with mitigation (p < 0.001), in those with maximum tumor diameter ≥10 cm compared to <10 cm (p < 0.001), and in stage IV compared to stage III patients (p = 0.036). The AUC values for maximum tumor diameter, degree of differentiation, and tumor stage were 0.703, 0.669, 0.574, and 0.598, respectively. The detection of CTCs provides significant insights into the clinical characteristics and prognosis of advanced pediatric NB, highlighting its potential as a prognostic tool.
A method is provided for producing motif-specific, context-independent antibodies which recognize a plurality of peptides or proteins within a genome that contain the same motif. The method includes the step of immunizing a host with a degenerate peptide library antigen featuring (i) a fixed target motif containing one or more invariant amino acids including at least one modified amino acid, and (ii) a plurality of degenerate amino adds flanking the motif. Motif-specific, context-independent antibodies produced by the disclosed method are also provided. The method encompasses motifs consisting of a single modified amino acid, as well as short motifs comprising multiple invariant amino acids including one or more modified amino acids, such as all or part of kinase consensus substrate motifs, protein-protein binding motifs, or other cell signaling motifs. Methods of using the antibodies, e.g. for genome-wide profiling, are also provided.
Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
PURPOSE: An anticancer and cancer sensitization composition containing an inhibitor RRP12 gene expression or RRP12 protein is provided to enhance anticancer effect and to develop an anticancer agent and anticancer aid. CONSTITUTION: An anticancer composition contains an inhibitor of RRP12(ribosomal RNA processing 12 homolog) gene or RRP12 protein activation as an active ingredient. The expression inhibitor is RRP12-specific siRNA, antisense oligonucleotide, aptamer, antibody, or single strand variable region fragment. The siRNA is selected from sequence number 5. A cancer sensitization composition contains the inhibitor. An anticancer composition contains the composition containing the inhibitor and anticancer agent, doxorubicin. A method for screening the anticancer agent or cancer sensitizer comprises: a step of treating a test material and analyzing RRP12 gene expression or RRP12 protein activation; and a step of determining the test material as the anticancer agent or cancer sensitizer when the expression or activation is suppressed after treating the test material.
Participants (\>= 3 months and \< 6 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
This is a feasibility study using a randomized controlled trial (RCT) design in which 100 Native Hawaiians (NHs) and other Pacific Islanders (PPs) will be randomized to either a 3-month diabetes self-management group (DSMG; N=50) or a delayed intervention control group (CG; N=50). Participants in the DSMG will receive culturally-tailored, group diabetes self-management education delivered in a community setting by trained community peer educators. To meet this objective, we have partnered with four community-based organizations: 1) Hawai'i Maoli Association of Hawaiian Civic Clubs, 2) Ke Ola Mamo Native Hawaiian Health Care System, 3) Kokua Kalihi Valley Comprehensive Family Services, and 4) Kula No Nā Po'e Hawai'i. These four organizations provide services to a large number of Pacific People to include, but not limited to, Native Hawaiians, Samoans, Filipinos, and Chuukese. They already have intervention research experience as members of the PILI 'Ohana CBPR Project. The 3-month face-to-face intervention will be community-based and community-led by trained community peer educators from these four partnering community organizations. Individuals with a hemoglobin A1c (HbA1c; average blood sugar levels) \>=8% will be recruited for the study because they represent the most at-risk for diabetes-related complications.

Over a 1-year accrual period, the community partners will recruit and enroll 100 eligible NHs and PPs (25 participants per a participating community), as well as deliver and evaluate the intervention in their respective community settings. The primary outcomes of our study are hemoglobin A1c and self-reported diabetes specific quality of life. Secondary outcomes are cholesterol levels (including HDL, LDL, total cholesterol, and triglycerides), blood pressure, body mass index, and psychosocial adaptation.
The invention discloses an industrialized production process of an anti-tumor medicine which is lentinan capsules. The invention belongs to the technical field of traditional Chinese medicine preparation. The invention aims at solving problems of poor medicine stability and poor medicine bioavailability of existing lentinan tablets. The method is characterized in that the lentinan capsules are prepared from raw materials of: 14.5-33 parts of lentinan, 170.5-152 parts of a filler calcium carbonate, and 45-49 parts of a wetting agent of 80% ethanol. The process comprises the steps that: (1) lentinan and calcium carbonate are fetched according to the ratio, and are respectively crushed into powder of 90-110 meshes; (2) the powder is mixed for 35-45min in a trough type mixing machine; the 80% ethanol is added according to the ratio; the mixture is mixed for 35-45min, such that a soft material is obtained; (3) the soft material is granulated in a granulator; and the granules are dried in a drying device; (4) the granules are sized in a granule sizing machine; (6) the granules are filled into capsules; the capsules are encapsulated in aluminum-plastic packages; the packages are packaged in small and middle boxes; and the boxes are packaged, such that the finished products are obtained. The production process provided by the invention is advantaged in high medicine stability and medicine bioavailability. With the method, the content of lentinan reaches 14.8mg/capsule. The method is mainly used for produce lentinan capsules.
BACKGROUND: A low-protein diet (LPD) is recommended to patients with advanced chronic kidney disease (CKD), whereas geriatric guidelines recommend a higher amount of protein. The aim of this study was to evaluate the safety of LPD treatment in older adults with advanced CKD.
METHODS: The EQUAL study is a prospective, observational study including patients ≥65 years of age with an incident estimated glomerular filtration rate <20 ml/min/1.73 m2 in six European countries with follow-up through 6 years. Nutritional status was assessed by a 7-point subjective global assessment (SGA) every 3-6 months. Prescribed diet (g protein/kg of bodyweight) was recorded on every study visit; measured protein intake was available in three countries. Time to death and decline in nutritional status (SGA decrease of ≥2 points) were analysed using marginal structural models with dynamic inverse probability of treatment and censoring weights.
RESULTS: Of 1738 adults (631 prescribed LPD at any point during follow-up), there were 1319 with repeated SGA measurements, of which 267 (20%) decreased in SGA ≥2 points and 565 (32.5%) who died. There was no difference in survival or decrease in nutritional status for patients prescribed a LPD ≤0.8 g/kg ideal bodyweight {odds ratio [OR] for mortality 1.15 [95% confidence interval (CI) 0.86-1.55)] and OR for decrease in SGA 1.11 [95% CI 0.74-1.66]} in the adjusted models. In patients prescribed a LPD <0.6 g/kg ideal bodyweight, the results were similar. There was a significant interaction with LPD and older age >75 years, lower SGA and higher comorbidity burden for both mortality and nutritional status decline.
CONCLUSIONS: In older adults with CKD approaching end-stage kidney disease, a traditional LPD prescribed and monitored according to routine clinical practice in Europe appears to be safe.